[CAS NO. 2361139-70-8] RIPK3-IN-1
PRODUCTS SPECIFICATIONS [2361139-70-8]
DESCRIPTION [2361139-70-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 512.53 |
| Molecular Formula | C29H25FN4O4 |
| SMILES | O=C(C1=CC=CN(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC(NC(C5CC5)=O)=NC=C4)C(C)=C3C |
1 Publications Citing Use of MCE
Summary
IC50 & Target
IC50: 9.1 nM (RIPK3), 5.5 μM (RIPK1), >10 μM (RIPK2) [1]
In Vitro
RIPK3-IN-1 (Compound 18) also inhibits ABL, BRAF/V599E, MAP4K3, and SRC with IC
50
s of 0.37, 0.15, 0.012, and 0.075 μM, respectively
[1]
.
Necroptosis is a programmed form of cell death and has been associated with a variety of diseases, including ischemia reperfusion injury, neurodegenerative disorders, pancreatic cancer, and autoimmune diseases such as inflammatory bowel disease (IBD). Upon stimulation of death receptors (such as the family of TNF receptors), signaling can initiate a necroptotic cell death process. This involves formation of a necrosome, which includes receptor interacting protein kinases 1 and 3 (RIPK1, RIPK3) in a cytosolic complex
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 5 mg/mL ( 9.76 mM ; ultrasonic and warming and heat to 80°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9511 mL | 9.7555 mL | 19.5111 mL |
| 5 mM | 0.3902 mL | 1.9511 mL | 3.9022 mL |
| 10 mM | --- | --- | --- |